pf-04457845 pf-04457845 jzp150 (formerly pf-04457845) is an inhibitor of the enzyme fatty acid amide hydrolase (faah), with an ic50 of 7.2nm, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen. jzp150clinical dataatc codenonelegal statuslegal status us: investigational new drug pharmacokinetic datametabolismcy3a4identifiers iupac name n-pyridazin-3-yl-4-oxyphenyl)methylidene]piperidine-1-carboxamide cas number1020315-31-4 ypubchem cid24771824chemspider26390839uniih4c81m8yywchemblchembl1651534comptox dashboard (epa)dtxsid00144539 chemical and physical dataformulac23h20f3n5o2molar mass455.441 g·mol−13d model (jsmol)interactive image smiles n4ncccc4nc(=o)n(cc3)cc\c3=c/c2cc(ccc2)oc(cc1)ncc1c(f)(f)f inchi inchi=1s/c23h20f3n5o2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15h,8-9,11-12h2,(h,29,30,32)key:batctbjijjephm-uhfffaoysa-n jzp150 is currently being developed by jazz pharmaceuticals and is in a phase 2 trial in the us for ptsd.